Background:To evaluate the early rate of change of best-corrected visual acuity (BCVA), central retinal sensitivity, neuroretinal and choroidal thickness in patients with macular edema after 1.25 mg/0.05 ml intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA). METHODS: A prospective, nonrandomized, interventional study. Thirty-seven consecutive eyes with macular edema were included in the study. For all eyes, BCVA, central retinochoroidal thickness at standardized A-scan, central retinal thickness, and central retinal sensitivity recorded with a spectral scanning laser ophthalmoscope optical coherence tomography/microperimeter device were evaluated at baseline and 7, 15, 30, 37, 45, and 60 days after initial treatment. All patients received 2 intravitreal bevacizumab injections at 1-month interval. RESULTS: A significant although not related improvement of BCVA and retinal sensitivity was seen after 1 month and 2 months of follow-up. Anatomic improvement only involved the neuroretina, although significant changes of central choroidal thickness were not detected. CONCLUSION: Intravitreal bevacizumab for macular edema determines significant early functional and anatomic improvements
Bevacizumab in macular edema: functional and anatomic changes in a prospective case series / Forte, Raimondo; Cennamo, G; Vecchio, Ec; Tenore, R; Aufiero, B; DE CRECCHIO, Giuseppe. - In: RETINA. - ISSN 0275-004X. - STAMPA. - 29:(2009), pp. 941-948. [10.1097/IAE.0b013e3181a3b8e7]
Bevacizumab in macular edema: functional and anatomic changes in a prospective case series.
FORTE, RAIMONDO;DE CRECCHIO, GIUSEPPE
2009
Abstract
Background:To evaluate the early rate of change of best-corrected visual acuity (BCVA), central retinal sensitivity, neuroretinal and choroidal thickness in patients with macular edema after 1.25 mg/0.05 ml intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA). METHODS: A prospective, nonrandomized, interventional study. Thirty-seven consecutive eyes with macular edema were included in the study. For all eyes, BCVA, central retinochoroidal thickness at standardized A-scan, central retinal thickness, and central retinal sensitivity recorded with a spectral scanning laser ophthalmoscope optical coherence tomography/microperimeter device were evaluated at baseline and 7, 15, 30, 37, 45, and 60 days after initial treatment. All patients received 2 intravitreal bevacizumab injections at 1-month interval. RESULTS: A significant although not related improvement of BCVA and retinal sensitivity was seen after 1 month and 2 months of follow-up. Anatomic improvement only involved the neuroretina, although significant changes of central choroidal thickness were not detected. CONCLUSION: Intravitreal bevacizumab for macular edema determines significant early functional and anatomic improvementsFile | Dimensione | Formato | |
---|---|---|---|
Bevacizumab in macular edema functional and anatomic changes in a prospective case series.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
825.67 kB
Formato
Adobe PDF
|
825.67 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.